Treatment of Urge Urinary Incontinence in Women After Failure of Cesa or Vasa (URGE II)
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Urge urinary incontinence can be a disorder caused by destroyed pelvic structures. We repaired the uteri-sacral ligaments (USL) by cesa or vasa. The study evaluates if solifenacin can lead to continence after surgery or if also the pubo-urethral ligaments (PUL) need to be repaired.
| Condition | Intervention | Phase |
|---|---|---|
|
Treatment of Urge Incontinence After Repair of the USL |
Procedure: TOT Drug: solifenacin |
Phase 1 Phase 2 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Crossover Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Phase 1/2 Study of the Effect of TOT or Solifenacin After Cesa or Vasa on Urge Urinary Incontinence |
- cure of incontinence [ Time Frame: 3 months ] [ Designated as safety issue: No ]
- improvement of urge symptoms [ Time Frame: 3 months ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 120 |
| Study Start Date: | January 2013 |
| Estimated Study Completion Date: | July 2016 |
| Estimated Primary Completion Date: | December 2015 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: trans obturatorial tape (TOT)
placement of a sub-urethral tape
|
Procedure: TOT
Other Name: trans obturatorial tape
|
|
Active Comparator: solifenacin
10 mg per day
|
Drug: solifenacin
Other Name: VESICUR 10mg per day
|
Detailed Description:
It was hypothesized that urge urinary incontinence in women is based on the destruction of the uteri-sacral ligaments (USL)and the pubourethral ligaments (PUL). In a preliminary study (URGE I) we repaired the USL by cesa or vasa. Those patients who are still incontinent after cesa and vasa get the repair of the PUL by means of trans-obturator tapes (TOT). That treatment is compared to conservative medical treatment. Cross over after completion of three months is possible if no continence is achieved.
Eligibility| Ages Eligible for Study: | 40 Years to 85 Years |
| Genders Eligible for Study: | Female |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- prior vasa or cesa operation as part of the URGE I study
- stress urinary incontinence
- mixed urinary incontinence
Exclusion Criteria:
- previous urogynecological surgery
- avulsion of cesa or vasa tape
- pregnancy
- neurologic/psychological reasons for incontinence
- body weight >100kg
- syndrome of dry overactive bladder
Contacts and Locations| Contact: Wolfram H Jager, PhD | 0049221478 ext 4900 | wolfram.jaeger@uk-koeln.de |
| Contact: Peter Mallmann, PhD | 0049221478 ext 4940 | peter.mallmann@uk-koeln.de |
| Germany | |
| Abt. Beckenbodenchirurgie der Universitäts-Frauenklinik Köln | Recruiting |
| Köln, NRW, Germany, 50931 | |
| Contact: Wolfram H Jager, PhD 0049221478 ext 4900 wolfram.jaeger@uk-koeln.de | |
| Abt. Beckenbodenchirurgie der Universitäts-Frauenklinik Köln | Recruiting |
| Köln, NRW, Germany, 50931 | |
| Contact: Wolfram H Jager, PhD 0049221478 ext 4900 wolfram.jaeger@uk-koeln.de | |
| Contact: Peter Mallmann, PhD 0049221478 ext 4940 peter.mallmann@uk-koeln.de | |
| Principal Investigator: Wolfram H Jager, PhD | |
More Information
No publications provided
| Responsible Party: | Professor Dr. Wolfram Jäger, Professor, Klinikum der Universität Köln |
| ClinicalTrials.gov Identifier: | NCT01737918 History of Changes |
| Other Study ID Numbers: | URGE II |
| Study First Received: | November 28, 2012 |
| Last Updated: | January 20, 2013 |
| Health Authority: | Ethical Committee of the University of Köln: Germany |
Keywords provided by Klinikum der Universität Köln:
|
urge urinary incontinence, cesa, vasa, TOT, solifenacin |
Additional relevant MeSH terms:
|
Urinary Incontinence Urinary Incontinence, Urge Urination Disorders Urologic Diseases Urological Manifestations Signs and Symptoms Quinuclidin-3'-yl-1-phenyl-1,2,3,4-tetrahydroisoquinoline-2-carboxylate monosuccinate |
Muscarinic Antagonists Cholinergic Antagonists Cholinergic Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Pharmacologic Actions Physiological Effects of Drugs |
ClinicalTrials.gov processed this record on May 16, 2013